Search
Vaborbactam
go.drugbank.com/drugs/DB12107ApprovedInvestigationalVaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore. … In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for the treatment of adult patients with complicated urinary tract infections (cUTI).
Momelotinib
go.drugbank.com/drugs/DB11763ApprovedInvestigationalMomelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. It is a competitive inhibitor of JAK ATP binding. … [L48186] Myelofibrosis (MF) is a group of myeloproliferative neoplasms characterized by abnormal proliferative hematopoietic stem cells, leading to the release of cytokines and growth factors.
Polysorbate 20
go.drugbank.com/drugs/DB11178ApprovedPolysorbate 20 is a wetting agent in food products, as well as washing agent, stabilizer and solubilizer in labratory assays and industrial applications. … It is also an excipient that stabilizes emulsions and suspensions in pharmaceutical products and lubricant in ophthalmic solutions.
Categories: Compounds used in a research, industrial, or household settingEthyl chloride
go.drugbank.com/drugs/DB13259ApprovedWithdrawnEthyl chloride is used as a diagnostic tool to detect a dead tooth with nonviable pulp. … Ethyl chloride, or chloroethane, has a chemical formula C2H5Cl. It was commonly used in the production of tetraethyllead (TEL), which is an additive for gasoline.
Reproxalap
go.drugbank.com/drugs/DB16688Investigational[L32990] NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.[L32990] … Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis
SYNB1020
go.drugbank.com/drugs/DB17667Investigationalto a lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study. … granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016;[L45988] however, the manufacturer discontinued further development of SYNB1020 to treat hyperammonemia due
Tegafur-uracil
go.drugbank.com/drugs/DB09327ApprovedTegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4. … It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.
Chromium Cr-51
go.drugbank.com/drugs/DB11140ApprovedInvestigationalChromium Cr-51 is an isotope of chromium that has been used as a radioactive label for decades. … It is used as a diagnostic radiopharmaceutical agent in nephrology to determine glomerular filtration rate,[A249765,A249770] and in hematology to determine red blood cell volume or mass, study the red
Celiprolol
go.drugbank.com/drugs/DB04846ApprovedInvestigationalWithdrawnIt is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. … In 2010 a clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular Ehlers–Danlos syndrome.
Lormetazepam
go.drugbank.com/drugs/DB13872ApprovedLormatazepam is an orally available benzodiazepine used in the UK for the treatment of short-term insomnia [L927].